Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

Completed · Phase 1

Conditions studied: End-Stage Kidney Disease

In brief

The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.

Key facts

Study ID

NCT00143741

Run by

University of Chicago

People needed

20

Starts

2005-05-01

Expected to finish

2011-07-01

Last updated by the study team

2013-01-10

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eighteen years or older,
• On the waiting list for a kidney transplant list
• On hemodialysis or peritoneal dialysis

You may not qualify if…

• Pregnant woman
• Patients who need ongoing blood products
• Patients with failed organs having active rejection
• Other therapies to decrease PRA
• Patients listed for multi-organ transplants (other than kidney-pancreas)

Where it is running

• The University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.